#begin document (wb/sel/20/sel_2098); part 000
wb/sel/20/sel_2098   0    0               and     CC            (TOP(FRAG*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    1        conclusion     NN               (NP(NP*)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    2                 :      :                     *      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    3                 "     ``                     *      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    4                On     IN                (S(PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    5               the     DT               (NP(NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    6             basis     NN                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    7                of     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    8               the     DT               (NP(NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0    9           results    NNS                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   10              from     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   11              GAIT    NNP             (NP*))))))     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   12                 ,      ,                     *      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   13                it    PRP              (NP(NP*))     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   14             seems    VBZ                  (VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   15           prudent     JJ             (S(ADJP*))     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   16                to     TO                (S(VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   17              tell     VB                  (VP*    tell  01   1   -   *      (V*)  -
wb/sel/20/sel_2098   0   18               our   PRP$               (NP(NP*      -    -   -   -   *   (ARG2*   -
wb/sel/20/sel_2098   0   19          patients    NNS                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   20              with     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   21       symptomatic     JJ               (NP(NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   22    osteoarthritis     NN                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   23                of     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   24               the     DT                  (NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   25              knee     NN                 *)))))     -    -   -   -   *        *)  -
wb/sel/20/sel_2098   0   26              that     IN                (SBAR*      -    -   -   -   *   (ARG1*   -
wb/sel/20/sel_2098   0   27           neither     CC             (S(NP(NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   28       glucosamine     NN                  (NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   29     hydrochloride     NN                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   30               nor     CC                     *      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   31       chondroitin     NN                  (NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   32           sulfate     NN                    *))     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   33             alone     RB               (ADVP*))     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   34               has    VBZ                  (VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   35              been    VBN                  (VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   36             shown    VBN                  (VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   37                to     TO                (S(VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   38                be     VB                  (VP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   39              more    RBR           (ADJP(ADJP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   40       efficacious     JJ                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   41              than     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   42           placebo     NN                 (NP*))     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   43               for     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   44               the     DT               (NP(NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   45         treatment     NN                     *)     -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   46                of     IN                  (PP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   47              knee     NN                  (NP*      -    -   -   -   *        *   -
wb/sel/20/sel_2098   0   48              pain     NN   *)))))))))))))))))))     -    -   -   -   *        *)  -
wb/sel/20/sel_2098   0   49                 .      .                    *))     -    -   -   -   *        *   -

#end document
